Commonly used combination treatment regimens with enasidenib

Enasidenib, as a targeted therapy drug, can usually be used in combination with other drugs to improve the therapeutic effect or reduce the side effects of treatment when treating patients with acute myeloid leukemia (AML) with IDH2 mutations. Combination drug use is a common strategy in modern cancer treatment, especially when a single drug has limited therapeutic effect. Combination drugs can often exert a synergistic effect to improve patient prognosis.

In clinical practice, the most common combination treatment regimen for ensidipine is combined with chemotherapy drugs or other targeted drugs. For example, ensidipine can be combined with cytarabine or other similar chemotherapy drugs. This combination is often used to enhance the treatment effect of AML. Cytarabine, a standard chemotherapy drug, can be combined with ensidipine to increase the death rate of leukemia cells and enhance the therapeutic effect through different mechanisms of action.

In addition, ensidipine can also be used in combination with other targeted therapies to intervene on multiple targets simultaneously during treatment. For example, ensidipine may be combined with an inhibitor of IDH1 mutations such as ivosidenib. Although IDH1 and IDH2 mutations exist separately in different patient populations, research suggests that in some AML patients, combining IDH1 and IDH2 inhibitors may enhance efficacy against leukemia.

The choice of combination therapy should be based on factors such as the patient's specific condition, previous treatment history, and drug interactions. During the actual treatment process, doctors will flexibly adjust the drug combination based on the patient's drug resistance, toxic reactions and treatment responses.

Although combining medications may increase the effectiveness of treatment, they may also increase the risk of side effects. Therefore, when patients receive combination therapy, they need to regularly monitor the efficacy and side effects to ensure the safety of drug treatment. Doctors should promptly adjust the treatment plan according to the patient's response to ensure the best treatment effect.

Reference materials:https://www.idhifa.com/